Buy Sun Pharma; target of Rs 2300: Choice Institutional Equities
Moneycontrol • 1 day ago
Key Investment Pillars
- Innovation-led expansion: Sun Pharma's innovative and specialty pipeline is expected to drive growth, with a strong launch pipeline and rising contribution from innovative medicines.
- India business outperformance: The company's India business is anticipated to continue outperforming the IPM, supported by strong prescription trends, market-share gains, and volume expansion.
- Organon acquisition: The acquisition is progressing well and is expected to strengthen Sun Pharma's position in the global innovative medicine market.
- R&D investment: The company's R&D expenditure is projected to increase, driven by clinical development activities and patient recruitment progress.
Thesis Validation Checklist
- Launch pipeline progress: Monitor the success of Sun Pharma's innovative and specialty launches, particularly in the US and emerging markets.
- India business growth: Track the company's India business performance, including market share gains and volume expansion.
- Organon acquisition integration: Assess the progress of the Organon acquisition integration and its impact on Sun Pharma's financials and operations.
- R&D milestones: Watch for significant R&D milestones, such as clinical trial results and regulatory approvals, which can drive long-term growth.